SAM
OCUL icon

Smartleaf Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Smartleaf Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.6K Sell
8,994
-223
-2% -$2.13K ﹤0.01% 1313
2025
Q4 		$112K Buy
9,217
+8,434
+1,077% +$102K ﹤0.01% 1121
2025
Q3 		$9.81K Buy
783
+705
+904% +$8.43K ﹤0.01% 2114
2025
Q2 		$719 Sell
78
-148
-65% -$1.16K ﹤0.01% 2530
2025
Q1 		$1.71K Buy
+226
New +$1.74K ﹤0.01% 2501

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Smartleaf Asset Management's OCUL Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Ocular Therapeutix (OCUL) stake by 2.4% in Q1 2026, selling an estimated $2.13K and leaving 8,994 shares worth $66.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1313.

Smartleaf Asset Management first reported a position in OCUL in Q1 2025 and has held it in 5 quarters since. The position peaked at $112K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Smartleaf Asset Management held 8,994 shares of Ocular Therapeutix worth $66.6K as of Q1 2026.
  • Smartleaf Asset Management sold 223 Ocular Therapeutix shares in Q1 2026, an estimated $2.13K.
  • Ocular Therapeutix made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1313 holding.
  • Smartleaf Asset Management first reported a position in Ocular Therapeutix in Q1 2025 and has held it in 5 quarters since.
  • Smartleaf Asset Management's Ocular Therapeutix position peaked at $112K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.